Table 3.

Distribution of patients and outcomes combining BCR‐ABL1 transcript levels at 4‐wk and 3‐mo

Group	VEMR	3 mos EMR	Number of patients	CCyR by 1 y	MMR by 1 y	CI of MMR by 5 y	CI of DMR by 5 y	OS by 5 y	PFS by 5 y	EFS‐aa by 5 y	EFS‐bb by 5 y
Group 1	Yes	Yes	89	83/89 (93.3%)	56/89 (62.9%)	91.7% ± 4.1	62.1% ± 10.1	98.8% ± 1.2	98.8% ± 1.2	92.3% ± 4.5	73.6% ± 7.1
Group 2		No	8	74/95 (77.9%)	22/95 (23.2%)	64.8% ± 9.7	33.8% ± 10.0	97.5% ± 1.7	96.9% ± 1.8	84.0% ± 4.1	56.7% ± 7.3
Group 3	No	Yes	87
Group 4		No	29	14/29 (48.3%)	2/29 (6.9%)	74.1% ± 21.5	20.0% ± 17.9	100%	100%	70.0% ± 11.8	48.2% ± 12.8
Log‐rank P				<0.0001	<0.0001	<0.0001	0.006	0.723	0.512	0.005	0.007
Log‐rank P between subgroups			Group 1 vs 2 and 3	0.006	0.001	<0.0001	0.063	0.603	0.389	0.013	0.016
			Group 1 vs 4	<0.0001	<0.0001	<0.0001	0.015	0.992	0.991	0.005	0.005
			Group 2 and 3 vs 4	0.002	0.121	0.169	0.342	0.971	0.967	0.385	0.285

2G TKI, second‐generation tyrosine kinase inhibition; CI, confidence interval; DMR, deep molecular response; EFS, event‐free survival; MMR, molecular response; OS, overall survival; PFS, progression‐free survival.

^aEFS‐a: PFS + ELN treatment failure + ELN warning.

^bEFS‐b: PFS + ELN treatment failure + ELN warning + frontline TKI discontinuation (except treatment free remission).